Background: Drugs that exhibit close margins between therapeutic and toxic blood concentrations are considered to have a narrow therapeutic index (NTI). The Food and Drug Administration has proposed that NTI drugs should have more stringent bioequivalence standards for approval of generic formulations. However, many immunosuppressant drugs do not have a well-defined therapeutic index (TI).
INTRODUCTION
Immunosuppression is an important aspect of successful organ transplantation. Cyclosporine, tacrolimus, and sirolimus are drugs that are commonly used for immunosuppression in transplant patients to prevent graft rejection. 1 However, the benefits of preventing rejection must be carefully balanced with the risks of drug toxicities, including increased risk of infections and malignancies. 2, 3 Immunosuppressive drugs are often considered to have a narrow therapeutic index (NTI), exhibiting a very close margin between therapeutic and toxic blood concentrations. 4 Small changes in the dose of an NTI drug can lead to changes in exposure that are associated with therapeutic failures if the therapeutic range is not reached, or unwanted side effects if the therapeutic range is exceeded.
In order for a new generic version of a drug to receive approval from the Food and Drug Administration (FDA), the manufacturer must demonstrate that the generic formulation is pharmaceutically equivalent and bioequivalent to the innovator formulation. 5 The current FDA bioequivalence criteria require that the 90% confidence interval of the ratio between the geometric mean of a generic product and the reference product fall within 80%-125%. 6 In 2010, the FDA proposed that drugs classified as NTI should have more stringent regulatory standards for the approval of generic formulations. The proposed new bioequivalence criteria require referencescaled bioequivalence testing and a variability comparison test for generic drugs with an NTI. 7 In order for these new standards to be implemented, it is necessary to define which drugs should be classified as NTI. NTI drugs generally have the following characteristics: (1) there is little separation between therapeutic and toxic doses (or the associated blood/plasma concentrations), (2) subtherapeutic concentrations may lead to serious therapeutic failure, (3) they are subject to therapeutic monitoring based on pharmacokinetic (PK) or pharmacodynamic (PD) measures, (4) they possess lowto-moderate (ie, no more than 30%) within-subject variability, and (5) doses are often adjusted in very small increments (less than 20%) in clinical practice. 8 NTI classification requires the estimation of therapeutic index (TI), which is not well established for many available immunosuppressants. Pollard et al 9 reported that conversion from innovator formulations to generic formulations of immunosuppressants has been associated with increased renal graft failure and biopsy-proven acute rejection (BPAR), which has led to a lack of confidence by providers in prescribing generic products. If certain immunosuppressants were to be identified as NTI drugs, application of the new criteria would be expected to improve patient safety, enhance physician confidence in generic products, and decrease health care costs due to increased generic drug prescription. The purpose of our study was to determine whether the medical literature can be used to determine the TI of immunosuppressants commonly used to prevent rejection in renal transplant patients. We focused our assessment on renal transplantation, as this is the most common type of organ transplantation, which has the largest body of literature regarding the use of immunosuppressant therapies.
MATERIALS AND METHODS
Through collaboration with the FDA and review of international regulatory agency documents, we focused on 3 immunosuppressants as candidate NTI drugs that may benefit from tighter bioequivalence standards for generic drug development: cyclosporine, tacrolimus, and sirolimus.
Literature Search
We performed a literature search with no time restriction to identify all studies reporting PK, safety, and efficacy data for these immunosuppressant drugs when used after the renal transplantation in adults using PubMed and Embase with the aid of professional librarians from Duke University Medical Library (Table 1) .
A study team member initially reviewed all identified article abstracts and selected those for full-text review that compared the efficacy or safety of the drug of interest to a comparator or contained therapeutic drug monitoring (TDM) information. Full-text articles meeting the study criteria and containing sufficient safety, efficacy, PKs or TDM data were included. When it was uncertain whether an article should be included and data extracted into the study database, the article was reviewed by a second study team member to reach consensus. As a quality assurance measure, 5% of the extracted data underwent an independent full review by a third study member.
For each immunosuppressant, we extracted efficacy and safety data from all prospective randomized controlled trials, and we extracted PK data from all identified PK studies into a study-specific drug database. Specific variables extracted included study demographics, drug dosing and formulation, PK parameters [eg, Cmax, area under the concentration versus time curve (AUC), clearance], and efficacy data (study phase, primary outcome, and study result). Safety data collected included warning and precautions listed in the drug label as well as all adverse events (AEs) with a placeboadjusted frequency of .10%.
Therapeutic Index Estimation
For each immunosuppressant drug, we reported the type and incidence of AE and the range of drug dosing and blood concentrations for which toxicity was described, the type and frequency of primary outcomes in efficacy studies, the blood drug concentration for which efficacy was described, and, when available, the effective versus toxic concentration and dose (therapeutic range). The efficacy of both cyclosporine and tacrolimus with mono-or combination therapy was most commonly assessed using 3 measures: (1) BPAR, (2) graft failure, and (3) patient death. Sirolimus efficacy with mono-or combination therapy was assessed using 3 similar measures: (1) BPAR; (2) patient death; and (3) a composite end point of death, graft loss, or BPAR. We extracted the minimum toxic concentration and the minimum effective concentration of the study population in the literature report and defined the TI as the ratio between the minimum toxic concentration to the minimum effective concentration. Although FDA does not specify a threshold value to determine whether a TI is narrow, in this analysis, we considered a TI #2 as one criterion to support the classification as an NTI drug.
RESULTS

Cyclosporine
Cyclosporine is a calcineurin inhibitor that has been used as an immunosuppressant for the prevention of rejection in renal transplant patients since the early 1980s. 10 Our literature search for cyclosporine yielded 373 articles with 122 articles containing data sufficient for extraction (Table 2) .
Safety
AEs associated with cyclosporine use in patients with renal transplant varied and involved many organ systems (Table 3) . [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Common AEs were hyperlipidemia; comparator-adjusted frequency, 21% 21 ; hypertension, 26% 22 ; cardiac events, 19% 23 ; gingival hyperplasia, 13%-43% 24, 25 ; and increased creatinine, 12%. 26 The incidence of AEs was not consistently shown to be dose related, and observed drug concentrations among those with certain AEs were often similar to those in patients without these events. 27, 28 One study of 118 renal transplant patients found no difference in cyclosporine PK parameters for patients who had nephrotoxicity ($25% increase in serum creatinine), liver toxicity, or posttransplant infection relative to peers without these conditions. 27 Cyclosporine nephrotoxicity potentially threatens renal allograft survival and provides a rationale for careful dose titration. [29] [30] [31] At least one study demonstrated that decreasing cyclosporine dose or stopping cyclosporine during the maintenance phase of immunosuppression led to the improved renal function over time compared with those who stayed on cyclosporine. 32 
Efficacy
Cyclosporine was typically administered as part of a multiple drug immunosuppressant regimen. Cyclosporine seemed to have similar efficacy to tacrolimus but greater efficacy than sirolimus and azathioprine. 13, 26, 33 A randomized trial comparing cyclosporine and prednisone to azathioprine and prednisone in cadaveric renal transplant patients found that cyclosporine resulted in better graft and patient outcomes than azathioprine. 33 Another randomized trial comparing cyclosporine and sirolimus to tacrolimus and sirolimus found that BPAR and graft survival were similar for the 2 regimens. 34 A third trial compared a combination immunosuppressant regimen containing cyclosporine to one containing sirolimus and found that patients receiving cyclosporine had lower rates of BPAR and death than those receiving sirolimus. 13 Efficacy was not entirely predicted by drug dose and concentration alone; rather, other PK parameters, such as AUC, seemed to better predict cyclosporine efficacy. 35 
Therapeutic Range and Drug Monitoring
Given available evidence, we were not able to determine the therapeutic range of cyclosporine; it seems to differ with time after transplantation, concomitant medications, and individual PKs. The ranges of drug exposure associated with efficacy in previous studies varied greatly in the first 3 months: trough concentrations, 120-350 ng/mL; peak (2-hour) concentrations, 700-2000 ng/mL; and AUC at 12 hours, 3000-8000 ng$h/mL (Table 3) . Target concentration ranges decreased over time, with some studies advocating for troughs as low as 50 ng/mL beyond one year posttransplant. 36 Furthermore, there seems to be notable overlap of these target values with those associated with AEs.
Therapeutic Index Estimation
The above estimates suggest a TI of 2-3 for cyclosporine. Yet, TDM and individualization of therapy based on clinical presentation are essential. 37, 38 The optimal PD target, timing, and specimen type that will predict efficacy while minimizing the risk for toxicity has not been well defined although several studies have attempted to do so (Table 4) . Trough concentrations are the most widely used metric for dose titration; however, the wide variability in absorption and PK, as well as an inconsistent correlation with clinical outcome, prompted search for other PD targets. [39] [40] [41] [42] Tacrolimus Tacrolimus is a newer calcineurin inhibitor that is now more commonly used than cyclosporine. 10 Our literature search for tacrolimus yielded 244 articles, 106 of which contained safety and/or efficacy data sufficient for extraction. 
Safety
AEs associated with tacrolimus use in renal transplant patients were varied (Table 2) . 11, 18, [43] [44] [45] [46] [47] [48] [49] Nephrotoxicity was the adverse effect most closely tied to tacrolimus dosing. 50 One study found that 3 of the 5 cases of nephrotoxicity were associated with tacrolimus trough concentrations .10 ng/ mL. 51 The analysis of 92 cadaveric renal transplant recipients found a linear association between increasing tacrolimus trough blood concentrations and higher rates of nephrotoxicity (increase from the posttransplant serum creatinine nadir by $0.5 mg/dL). 52 The relationship between the frequency of infection and the concentration of tacrolimus was unclear. One study found that there was no difference in the proportion of patients developing a bacterial, viral, or fungal infection when the goal trough concentration was 1.5-3 ng/mL compared with a goal trough concentration of 4-7 ng/mL, 53 and another study noted no infections in patients with trough concentrations .10 ng/mL. 51 A third study found that the trough and peak tacrolimus concentrations were higher in patients who developed an infection within 6 weeks of their renal transplant than in patients who did not develop an infection. 54 
Efficacy
Tacrolimus was typically given with other immunosuppressant agents, which varied based on immunologic parameters at the time of transplant and clinician preference. Dosing was most commonly based on blood trough levels, with target trough concentrations varying widely from 1.5 to 40 ng/mL. 48, 53 Target trough concentrations were typically higher in the 1-3 months immediately after the transplantation. A lower target trough concentration was often used as the time since transplantation increased. [55] [56] [57] [58] A large multicenter, randomized, controlled trial in renal transplantation demonstrated that a tacrolimus-based immunosuppressant regimen with a low goal trough concentration of 3-7 ng/mL resulted in a superior mean glomerular filtration rate and graft survival with a lower incidence of acute rejection than the comparator arms. 12 
Therapeutic Range and Drug Monitoring
The dose range associated with efficacy and toxicity partially overlapped. Efficacy did not seem to always be concentration related (Table 4) . 55, [59] [60] [61] The toxicity of tacrolimus increased gradually with increasing blood concentrations in some studies, 48, 51, 55, 62 whereas in others, the relationship was less clear (Table 3) . 48, 53, 61, 63 Blood concentrations in patients without toxicity often did not differ significantly from others who experienced adverse effects. 54 
Therapeutic Index Estimation
Based on the available medical literature, the optimal therapeutic range for tacrolimus is variable and the TI could not be estimated; therefore, we were unable to use the TI as a means of classifying tacrolimus as an NTI drug.
Sirolimus
Sirolimus is an inhibitor of the mammalian target of rapamycin and is sometimes used instead of or with a calcineurin inhibitor in renal transplant patients. 64 Our literature search for sirolimus yielded 142 articles, 45 of which contained safety and/or efficacy data sufficient for extraction.
Safety
AEs associated with sirolimus' use in renal transplant patients were varied (Table 2) . [65] [66] [67] [68] [69] [70] The prevalence of AEs associated with sirolimus was dose related in some studies. 65, 67 The incidence of AEs including malignancy, anemia, hypertension, abnormal kidney function, and upper respiratory infection was significantly higher in patients receiving the sirolimus and cyclosporine combination therapy compared with sirolimus monotherapy. 71, 72 Efficacy Sirolimus was administered as monotherapy or in conjunction with calcineurin inhibitors, such as tacrolimus or mycophenolate mofetil, to provide steroid-free immunosuppression. The effective dose range of sirolimus varied widely (0.5-5 mg/d) and may have been related to coadministered immunosuppressant drugs (eg, cyclosporine, tacrolimus, and steroids).
Therapeutic Range and Drug Monitoring
The dose range associated with efficacy and toxicity partially overlapped with both 100% patient survival and a high incidence of hyperlipidemia and new onset diabetes mellitus occurring at doses of 2-4 mg/d. 67, 73 Overall toxicity of sirolimus increased gradually with increasing blood concentrations. Blood concentrations in patients with favorable immunosuppressant outcomes did not differ significantly from blood concentrations in patients who experienced AEs (Tables 3 and 4) . Data from 150 renal transplant recipients on a regimen of sirolimus, cyclosporine, and prednisone found an association between trough sirolimus concentrations and both AEs and efficacy. Sirolimus concentrations ,5 ng/mL were predictive of acute rejection, whereas concentrations .15 ng/mL were linked with hypertriglyceridemia, thrombocytopenia, and leukopenia. 74 For patients receiving sirolimus with a calcineurin inhibitor and a corticosteroid, a therapeutic range of 5-12 ng/mL has been recommended. 75, 76 If the regimen does not include a calcineurin inhibitor, a higher range (12-24 ng/mL) has been recommended. 75, 76 TDM is recommended for the use of sirolimus in all patients especially in those likely to have altered drug metabolism and who are at high risk for rejection.
Therapeutic Index Estimation
Based on the available medical literature, the optimal therapeutic range for sirolimus varies depending if it is coadministered with a calcineurin inhibitor or not. As a result, more than one TI can be derived.
DISCUSSION
Our comprehensive literature search identified many studies evaluating the safety, efficacy, and PK data for these immunosuppressant drugs. The published literature indicates that cyclosporine has a TI of 2-3. Although we found sirolimus to have a therapeutic range of 5-12 ng/mL and tacrolimus to have a therapeutic range of 5-20 ng/mL, based on published studies, we were unable to estimate the TIs for sirolimus and tacrolimus.
Although studies considering a wide range of medications have demonstrated bioequivalence of generic medications to innovator medications, there are considerable concerns among physicians and patients regarding the safety and efficacy of generic immunomodulators. 4, [77] [78] [79] Although much of the evidence for these concerns is anecdotal, retrospective database studies seemed to suggest worse outcomes for renal transplant patients receiving generic formulations. A single-center retrospective review found that 88 renal transplant patients treated with a generic cyclosporine formulation were significantly more likely to experience BPAR than 100 patients treated with innovator cyclosporine. 80 The analysis of a large database generated as a part of the Collaborative Transplant Study found that the 397 patients treated with generic cyclosporine had 10% lower graft survival at one-year posttransplant than the 16,801 patients treated with the innovator formulation (P , 0.01). 9 However, the interpretation of these retrospective studies is challenging because there may be unrecorded differences between the patients who received the generic and those who received the innovator product. We are not aware of any studies demonstrating a difference in clinical outcomes for renal transplant patients receiving a generic formulation of tacrolimus compared with the innovator formulation. However, an average decrease of 12% in the concentration-to-dose ratio has been described when switching from innovator tacrolimus to a generic formulation while some other studies suggest similar dosing requirements and trough concentrations between the generic and innovator treatment arms. [81] [82] [83] [84] Most of these studies recommend close TDM when changing a patient from innovator to generic formulations, which may offset cost saving associated with the use of generic formulations. 77, 78 Studies comparing the effectiveness of generic formulations of sirolimus with the innovator formulation have not yet been published. Use of tighter bioequivalence standards for generic formulations of certain drugs, could result in decreased toxicity and sustained efficacy for patients switching from brand-name formulations. Clinicians and patients could then have more confidence in the less expensive products, likely leading to health care cost savings. Tighter bioequivalence standards, however, are not as necessary for drugs that have a wide TI, as larger variations in patient exposure can be well tolerated. Identification of NTI drugs is, therefore, key to the implementation of new bioequivalence standards.
In our study, we used a comprehensive literature search to assess the TI of certain immunosuppressants used in renal transplant patients. A TI ,2 is one criterion used to determine whether these drugs could be classified as NTI based on available evidence. Health Canada, the European Medicines Agency, and FDA consider cyclosporine to be an NTI drug. 85 We were not able to calculate the TI for tacrolimus or sirolimus. Tacrolimus has been considered to be an NTI drug by experts in the United States and internationally and is so classified by the FDA, European Medicines Agency, and Health Canada. For all 3 of these drugs, TDM is necessary in at least some clinical situations, and there are some concentration-dependent effects on efficacy and toxicity. The routine use of TDM in clinical practice suggests a clinical consensus that an NTI may be present and that more stringent testing of the PK and quality control properties should be performed before approval of generic formulations. In fact, after our data collection and analysis had been completed, the FDA recommended that sirolimus be considered to have an NTI. 86 Approval of generic formulations of these drugs with stringent testing of PK and quality control properties could reduce the potential risk of adverse effects or therapeutic failure.
An advantage of our study is the inclusion of an exhaustive systematic review of all of the toxicity and efficacy data available in the medical literature for these immunomodulators. Based on the compiled information, we were able to calculate therapeutic indices for cyclosporine to aid in its consideration as NTI drugs. Our study is limited by the method of literature review: our results are based on a wide variety of trials that included different drug dosages, therapeutic targets, and monitoring regimens. Thus, the results of our review may be strengthened when combined with other methods to support an NTI classification, including PK-PD modeling approaches, to determine which drugs should be subjected to more stringent bioequivalence criteria by regulatory agencies. Because most renal transplant patients receive more than one immunosuppressive medication, it is difficult to fully attribute efficacy or safety to the concentration of a single drug. We reported comparator-adjusted AEs where possible in an attempt to better quantify AEs attributable to the drug of interest. A better source of data regarding safety and efficacy of generic formulations would be prospective clinical trials in which patients are randomized to continuing on brand-name formulations versus switching to a generic formulation. However, such trials usually require a large number of study subjects to draw conclusions on the difference or equivalence in safety or efficacy outcomes, and it is not feasible to compare all possible NTI innovator drugs to all possible generic formulations. Most of the studies included in our analysis did not describe the laboratory technique(s) used to determine the blood concentration of the drug of interest. Differences in techniques between studies or over time may account for a range of values associated with toxicity and efficacy. Finally, our estimation of the TI was based on the population therapeutic range, which may be wider than that of an individual. Therefore, we may have overestimated the TI that can be applied to an individual.
CONCLUSIONS
A systematic literature review approach offers a lowcost alternative method to estimate the TI of these drugs when sufficient data are available. However, our method cannot overcome significant gaps in the literature. Although current literature does not provide a clear indication that these drugs have an NTI, the routine use of TDM in clinical practice suggests that more stringent testing of their PK and PD properties should be performed before the approval of generic formulations to ensure bioequivalence in the clinical setting.
